| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/29/2006 | US20060142296 4(Phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders |
| 06/29/2006 | US20060142295 Method of treating cancer with quinolone carboxylic acid derivatives |
| 06/29/2006 | US20060142294 Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| 06/29/2006 | US20060142293 e.g. 4-[5-(Piperidine-1-carbonyl)-furan-2-ylmethyl]-2H-phthalazin-1-one; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic agent with BRCA2 deficient phenotype; septic shock; ischemic injury; hemorrhagic shock; multiple sclerosis |
| 06/29/2006 | US20060142292 Water-soluble phenylpyridazine derivative and medicine containing the same |
| 06/29/2006 | US20060142290 Compositions for affecting weight loss |
| 06/29/2006 | US20060142289 Method of treating migraine headaches |
| 06/29/2006 | US20060142288 Combinations and methods for headaches |
| 06/29/2006 | US20060142287 Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer |
| 06/29/2006 | US20060142286 Cyclic hydroxylamine as psychoactive compounds |
| 06/29/2006 | US20060142285 for lowering blood glucose levels; insulin resistance; for use in drugs, foods, and beverages |
| 06/29/2006 | US20060142284 Cyclin dependent kinases (CDK2) inhibitors; 4-[5-(3-bromo-phenyl)-2H-pyrazol-3-ylamino]-benzenesulfonamide; cancer and hyperproliferative diseases, such as psoriasis |
| 06/29/2006 | US20060142283 Crystalline form IV of linezolid |
| 06/29/2006 | US20060142282 Combination effective for the treatment of impotence |
| 06/29/2006 | US20060142281 Indolinone derivatives |
| 06/29/2006 | US20060142280 Such as 4-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-benzo[d][1 ,3]oxazin-6-yl)-thiophene-2-carbonitrile; estrogen receptor agonists, progesterone receptor antagonists; hormone replacement therapy |
| 06/29/2006 | US20060142279 Treatment of latent tuberculosis |
| 06/29/2006 | US20060142278 Mitotic kinesin inhibitors |
| 06/29/2006 | US20060142277 Substituted aralkyl derivatives |
| 06/29/2006 | US20060142276 Therapeutic agent for senile dementia |
| 06/29/2006 | US20060142275 Enzyme inhibitors; a 1H-imidazo[1,2-a][1,4]benzodiazepine or tetrahydroimidazo[1,2a]pyrazine derivatives; antitumor agents for treating cancer of breast, colon, pancreas, prostate, lung, ovarian, epidermal, and hematopoietics |
| 06/29/2006 | US20060142274 Use of selected CGRP antagonists for combating menopausal hot flushes |
| 06/29/2006 | US20060142273 Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine |
| 06/29/2006 | US20060142272 Antitumor agents and process to prepare compound hybrids for anticancer agents |
| 06/29/2006 | US20060142271 Novel lapacho compounds and methods of use thereof |
| 06/29/2006 | US20060142270 Preventing or treating agent for glaucoma |
| 06/29/2006 | US20060142269 New compounds |
| 06/29/2006 | US20060142268 1,4,5,6-tetrahydroimidazo[4,5-d]benzazepine derivative or salt thereof |
| 06/29/2006 | US20060142267 [6-hydroxy-2-(2-hydroxy-benzyl)-benzo [b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; [6-hydroxy-2-(2-hydroxy-benzyl)-naphthalen-1-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone; 6-(2-hydroxy-benzyl)-5-{hydroxy-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methyl}-naphthalen-2-ol |
| 06/29/2006 | US20060142266 Compounds and their uses |
| 06/29/2006 | US20060142265 Compositions comprising multiple bioactive agents, and methods of using the same |
| 06/29/2006 | US20060142264 Novel amide derivatives |
| 06/29/2006 | US20060142263 Such as 5-bromo-thiophene-2-carboxylic acid-{1-[3-chloro-4-(2-oxo-[1,3]oxazinan-3-yl)-phenyl]-5-oxo-pyrrolidin-3-yl}-amide |
| 06/29/2006 | US20060142262 4-[1-(4-Methanesulfonyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy]-piperidine-1-carboxylic acid tert-butyl ester, for example, as antidiabetic and antiobesity agents |
| 06/29/2006 | US20060142261 Crystalline anhydrous cefdinir and crystalline cefdinir hydrates |
| 06/29/2006 | US20060142260 Water-soluble anionic bacteriochlorophyll derivatives and their uses |
| 06/29/2006 | US20060142259 Compounds, pharmaceutical compositions and methods for inhibiting HIV infectivity |
| 06/29/2006 | US20060142258 Estrogen replacement therapy |
| 06/29/2006 | US20060142257 Male contraceptive formulation comprising norethisterone |
| 06/29/2006 | US20060142256 Composition comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometricosis |
| 06/29/2006 | US20060142255 Hypocholesteremic preparations containing phytostenolesters of conjugated fatty acids, and methods of reducing serum cholesterol levels using the same |
| 06/29/2006 | US20060142254 Antipyretic preparation containing xylitol |
| 06/29/2006 | US20060142253 Methods for treating neoplastic, angiogenic, vascular, fibroblastic, and/or immunosuppressive irregularities of the eye and/or joint via administration of combretastatin based medicaments, and iontophoretic devices for delivering combretastatin based medicaments |
| 06/29/2006 | US20060142252 Tubulin binding agents and corresponding prodrug constructs |
| 06/29/2006 | US20060142251 Anti-microbial agents derived from methionine sulfoximine analogues |
| 06/29/2006 | US20060142250 Protein tyrosine phosphatase inhibitors and methods of use thereof |
| 06/29/2006 | US20060142249 Ophthalmic use |
| 06/29/2006 | US20060142248 Xanthurenic acid derivative pharmaceutical compositions and methods related thereto |
| 06/29/2006 | US20060142247 Tricyclic heterocycles |
| 06/29/2006 | US20060142246 2-Methylene-19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and its uses |
| 06/29/2006 | US20060142245 Inhibitors of hedgehog signaling pathways, compositions and uses related thereto |
| 06/29/2006 | US20060142244 Geranyl compounds |
| 06/29/2006 | US20060142243 Promoting repair of skin and mucous membrane tissues, the product of the present invention exhibits unique effects for controlling inflammation, damage, infection, and exudation; side effect reduction; topical administration |
| 06/29/2006 | US20060142242 Starch derivatives and other derivatives, production processes therefor, and wound healing applications therefor |
| 06/29/2006 | US20060142241 Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis |
| 06/29/2006 | US20060142240 Using isoguanosine nucleoside analogs, and derivatives thereof, in cell cultures and in antiviral therapy; increasing the mutation rate of a virus such as bovine viral diarrhea virus and hepatitis C virus |
| 06/29/2006 | US20060142239 Potassium or sodium salt of (-)-2-(4-hydroxyphenyl)ethyl!-thio-3-'4-{4-'(methzlsulfonzl)oxy !phenoxy}phenyl!propanoic acid and their use in medicine |
| 06/29/2006 | US20060142238 Chemical compounds |
| 06/29/2006 | US20060142237 e.g. N6-2-(4-aminophenyl)ethyladenosine (APNEA), N6-(4-amino-3-iodobenzyl)adenosine-5'-(N-methyluronamide) (AB-MECA), N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (IB-MECA), or 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide; adenosine receptor agonist (A3RAg), adenylyl cyclase inhibitor |
| 06/29/2006 | US20060142236 Antisense oligonucleotide modulation of raf gene expression |
| 06/29/2006 | US20060142235 Method of reducing and treating UVB-induced immunosuppression |
| 06/29/2006 | US20060142231 DNA damage repair inhibitors for treatment of cancer |
| 06/29/2006 | US20060142227 Amphiphylic peptide-PNA conjugates for the delivery of PNA through the blood brain barrier |
| 06/29/2006 | US20060142224 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 06/29/2006 | US20060142217 Bactericides for antibiotic-resistant Micrococcus, Streptococcus, Enterococcus or Staphylococcus; pure saccharide antibiotics; 4-((3-(trifluoromethyl-)phenyl)-amino-carbonylamino-),4,5-(dihydroxy-),6-(hydroxymethyl-)tetrahydropyran-2-yl)-),5-(undecanoylamino-),6-(hydroxymethyl-)tetrahydropyran |
| 06/29/2006 | US20060142216 Parasiticidal composition |
| 06/29/2006 | US20060142215 Tetracyclic bicyclolides |
| 06/29/2006 | US20060142214 Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation |
| 06/29/2006 | US20060142213 Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein |
| 06/29/2006 | US20060142212 Nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 06/29/2006 | US20060142211 Chromones and chromone derivatives and uses thereof |
| 06/29/2006 | US20060142210 Metabolic disorders like diabetes; sodium-dependent glucose cotransporter inhibitors; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene |
| 06/29/2006 | US20060142209 Glucopyranosyloxypyrazole derivatives and medicinal use thereof |
| 06/29/2006 | US20060142208 Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
| 06/29/2006 | US20060142207 Increased uptake of glucose-antineoplastic agents in cancer cells |
| 06/29/2006 | US20060142206 Novel difluorinated gem compounds, preparation methods thereof and applications of same |
| 06/29/2006 | US20060142204 Pyrrolidine derivatives for use in treating heaptitis c virus infection |
| 06/29/2006 | US20060142203 Antiproliferative agents; angiogenese inhibitors; antiinflammatory agents; anticancer agents |
| 06/29/2006 | US20060142202 Compositions and methods for targeted delivery of immune response modifiers |
| 06/29/2006 | US20060142197 TNF receptor and steroid hormone in a combined therapy |
| 06/29/2006 | US20060142196 Soluble GDNFR (Glial-cell Derived Neurotrophic Factor) that retains both ligand binding, and receptor signaling function (via Ret receptor tyrosine kinase) used to impart, restore, or enhance GDNFR alpha -ligand (preferably GDNF) responsiveness to cells; kidney diseases |
| 06/29/2006 | US20060142186 Administering a synergistic combination of a gonadotropin releasing hormone analog, leuprolide acetate, and either or both of an acetylcholinesterase inhibitor donepezil, rivastigimine, galantamine, and/or tacrine and an N-methyl-D-aspartate receptor antagon , memantine; sex steroid antagonists |
| 06/29/2006 | US20060142184 Protein based oral lubricant |
| 06/29/2006 | US20060142183 Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections |
| 06/29/2006 | US20060142180 Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors |
| 06/29/2006 | US20060142179 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders |
| 06/29/2006 | US20060142178 Method of treating cancer |
| 06/29/2006 | US20060141599 Crystals of Glucokinase and methods of growing them |
| 06/29/2006 | US20060141589 Method of producing macrolide compound |
| 06/29/2006 | US20060141580 Encoding protein with immunomodulatory activity, antiviral activity, and antitumor activity; treating any Type 1 interferon treatable disease including cancer; determining if a patient will respond to interferon treatment; transgenic animals |
| 06/29/2006 | US20060141550 Novel metabolic targets and markers |
| 06/29/2006 | US20060141476 Growth arrest homeobox gene |
| 06/29/2006 | US20060141472 Medical use of ras antagonists for the treatment of capillary malformation |
| 06/29/2006 | US20060141455 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 06/29/2006 | US20060141128 Process for producing coated preparation |
| 06/29/2006 | US20060141082 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity |
| 06/29/2006 | US20060141081 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
| 06/29/2006 | US20060141080 Extracting crushed plant material Cuminum cyminum with water or 50% aqueous alcoholic solvent; extracting a portion of the aqueous extract with n-butanol, separating -butanol layer and an aqueous layer, evaporating, and freeze drying the aqueous layer |
| 06/29/2006 | US20060141075 Methods and compositions for weight management and mood enhancement |
| 06/29/2006 | US20060141073 Oral care composition containing extract of unoxidized Camellia |